Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - heparin sodium, quantity: 2000 iu/l - injection, solution - excipient ingredients: water for injections; sodium chloride; citric acid monohydrate; dibasic sodium phosphate dodecahydrate - indications as at 11 july 2003: heparin sodium in 0.9% sodium chloride intravenous infusion is indicated as an anticoagulant in extracorporeal circulation, dialysis procedures, and as an aid in the maintenance of catheter patency.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - heparin sodium, quantity: 1000 iu/l - injection, solution - excipient ingredients: sodium chloride; citric acid monohydrate; dibasic sodium phosphate dodecahydrate; water for injections - indications as at 11 july 2003: heparin sodium in 0.9% sodium chloride intravenous infusion is indicated as an anticoagulant in extracorporeal circulation, dialysis procedures, and as an aid in the maintenance of catheter patency.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 50 g/l; sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 400 mg/l; calcium chloride dihydrate, quantity: 270 mg/l - injection, solution - excipient ingredients: water for injections - compound sodium lactate solution and 5% glucose is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are compatible with the solutions.

Singapura - Inggeris - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - general hospital - this device is indicated for use in the treatment of patients with renal failure to provide pd fluid exchanges with baxter homechoice pd systems in clinical and home use settings.

Singapura - Inggeris - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - general hospital - the solution administration set will be used to administer fluids to a patient's vascular system from a container through a needle or catheter inserted into a vein. the proposed solution set will be primarily used to administer solutions containing the chemotherapeutic drug paclitaxel and also used for general solution administration with baxter flo-gard and colleague volumetric infusion pumps.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - flumazenil, quantity: 1 mg - injection, solution - excipient ingredients: disodium edetate; sodium chloride; water for injections; sodium hydroxide; glacial acetic acid - flumazenil-baxter is indicated for use in hospitalised patients for the reversal of acute benzodiazepine effects (overdose or therapeutic). hospitalised patients are patients admitted to hospital, inpatient care and under continued professional observation while under the influence of flumazenil-claris. not to be used in outpatients or short stay patients. not to be used as a diagnostic.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - flumazenil, quantity: 0.5 mg - injection, solution - excipient ingredients: water for injections; sodium hydroxide; disodium edetate; glacial acetic acid; sodium chloride - flumazenil-baxter is indicated for use in hospitalised patients for the reversal of acute benzodiazepine effects (overdose or therapeutic). hospitalised patients are patients admitted to hospital, inpatient care and under continued professional observation while under the influence of flumazenil-claris. not to be used in outpatients or short stay patients. not to be used as a diagnostic.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ketamine hydrochloride, quantity: 115.34 mg/ml (equivalent: ketamine, qty 100 mg/ml) - injection, solution - excipient ingredients: water for injections; nitrogen - ketamine-baxter is recommended: 1. as the sole anaesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. ketamine-claris is best suited for short procedures and it can be used with additional doses, for longer procedures; 2. for the induction of anaesthesia prior to the administration of other general anaesthetic agents; 3. to supplement low-potency agents, such as nitrous oxide.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium hydroxide; hydrochloric acid; nitrogen; water for injections; sodium chloride - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ketorolac trometamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; ethanol; nitrogen; water for injections; hydrochloric acid; sodium hydroxide - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).